Biotech Values

[DewDiligence]

Roche—Tecentriq/Avastin shows statisg-better PFS vs Sutent monotherapy in first-line RCC for PD-L1-positive subgroup, but not for entire phase-2 trial:

http://www.roche.com/media/store/releases/med-cor-2017-02-18.htm

The study showed that people whose disease expressed PD-L1 (programmed death-ligand 1) and were treated with TECENTRIQ plus Avastin had a 36 percent reduction in the risk of…[PFS]… compared to people treated with sunitinib alone (median progression-free survival [mPFS]: 14.7 vs. 7.8 months; HR= 0.64; 95% CI 0.38, 1.08).

No PFS advantage was observed compared to sunitinib in the intention-to-treat [ITT] population (mPFS: 11.7 vs. 8.4 months; HR = 1.00; 95% CI 0.69, 1.45). Median Duration of Response (DoR) has not yet been reached after 20.7 months of follow-up across treatment arms.

In this trial, the PD-L1-positive subgroup was defined as patients with PD-L1 expression ≥1%.